Renew Your Membership

Michael R. Jaff, DO, FACC

Professional Bio:

Michael R. Jaff, DO is the Chief Medical Officer and Vice-President of clinical affairs, technology and innovation at Boston Scientific Corporation. A professor of medicine at Harvard Medical School, Dr. Jaff was the President of Newton-Wellesley Hospital from October 2016-December 2019. Prior to that, Dr. Jaff was the inaugural Paul and Phyllis Fireman Endowed Chair of Vascular Medicine and Medical Director of the Fireman Vascular Center at the Massachusetts General Hospital. He is an expert in all aspects of vascular medicine, including peripheral artery disease, venous thromboembolic disease, aneurysmal diseases, and all diagnostic strategies in vascular medicine. He is the founder of VasCore, the Vascular Ultrasound Core Laboratory, the largest of its’ kind in the United States. VasCore has participated in trial design and independent analysis of vascular laboratory images for over 200 prospective multicenter peripheral vascular device and pharmaceutical trials across 66 countries. Dr. Jaff has published extensively in the field of Vascular Medicine with over 300 peer-reviewed publications and 10 textbooks, is the Past-President of the Society for Vascular Medicine and Biology and was the first physician to have received the designation as Master of the Society for Vascular Medicine. He is a Fellow of the American College of Physicians, American College of Cardiology, the American Heart Association, and the Society for Cardiovascular Angiography and Intervention, and is a registered physician in vascular interpretation (RPVI). In November 2011, Dr. Jaff became an alumnus of Harvard Business School after completing the General Management Program.

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Vascular Therapies(MODEST), Micell(MODEST), Volcano/Philips(MODEST), AOPA(MODEST), Medtronic Vascular(SIGNIFICANT), Biotronik(NONE), Sanofi-Aventis(MODEST), Silk Road Medical(MODEST) OWNERSHIP/PARTNERSHIP/PRINCIPAL: Primacea(MODEST), Sano V(MODEST), PQ Bypass(MODEST), Janacare(NONE), MC10(NONE), Northwind(MODEST), Embolitech(SIGNIFICANT), Gemini(MODEST) OTHER FINANCIAL BENEFIT: Boston Scientific(NONE), Abbott Vascular(NONE), Vactronix(MODEST), Venarum(MODEST)

View Full Disclosure

From JACC: Low-Density Lipoprotein Cholesterol Testing Following MI Hospitalization Among Medicare Beneficiaries

Mar 19, 2024   |  Alison Bailey, MD, FACC; Vera Bittner, MD, FACC; C. Noel Bairey Merz, MD, MACC

Podcast

In this interview, C. Noel Bairey Merz, MD, FACC, and Vera Bittner, MD, MSPH, FACC, discuss Low-Density Lipoprotein Cholesterol Testing Following MI Hospitalization Among Medicare Beneficiaries.

Clinical Topics: Cardiovascular Care Team, Dyslipidemia, Lipid Metabolism, Nonstatins, Prevention

Keywords: ACCELLite, Myocardial Infarction, Medicare, Cholesterol, LDL

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

May 16, 2023   |  Dharam J. Kumbhani, MD, SM, FACC

Clinical Trial

The goal of the ODYSSEY OUTCOMES trial was to compare the safety and efficacy of alirocumab compared with placebo among patients with recent acute coronary syndrome (ACS) already on intensive or maximum-tolerated statin therapy.

Clinical Topics: Acute Coronary Syndromes, Cardiac Surgery, Cardiovascular Care Team, Diabetes and Cardiometabolic Disease, Dyslipidemia, Geriatric Cardiology, Invasive Cardiovascular Angiography and Intervention, Prevention, Pulmonary Hypertension and Venous Thromboembolism, Vascular Medicine, Atherosclerotic Disease (CAD/PAD), Cardiac Surgery and Arrhythmias, Lipid Metabolism, Nonstatins, Novel Agents, Statins, Interventions and ACS, Interventions and Vascular Medicine

Keywords: ACC22, ACC Annual Scientific Session, ACC19, AHA18, AHA Annual Scientific Sessions, ACC18, Acute Coronary Syndrome, Antibodies, Monoclonal, Angina, Unstable, Apolipoproteins, Apolipoproteins A, Apolipoproteins B, Brain Ischemia, Cholesterol, HDL, Cholesterol, LDL, Coronary Disease, Cost-Benefit Analysis, Diabetes Mellitus, Dyslipidemias, Geriatrics, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipids, Myocardial Infarction, Myocardial Revascularization, Peripheral Arterial Disease, Secondary Prevention, Stroke, Treatment Outcome, Venous Thromboembolism

Results 1-2 of 2